Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort

BACKGROUND: There is currently no standard second-line treatment for metastatic pancreatic adenocarcinoma (MPA), and progression-free survival is consistently <4 months in this setting. The aim of this study was to evaluate the efficacy and tolerability of Nab-paclitaxel plus gemcitabine (A+G) af...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Portal, Alix, Pernot, Simon, Tougeron, David, Arbaud, Claire, Bidault, Anne Thirot, de la Fouchardière, Christelle, Hammel, Pascal, Lecomte, Thierry, Dréanic, Johann, Coriat, Romain, Bachet, Jean-Baptiste, Dubreuil, Olivier, Marthey, Lysiane, Dahan, Laetitia, Tchoundjeu, Belinda, Locher, Christophe, Lepère, Céline, Bonnetain, Franck, Taieb, Julien
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2015
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4651133/
https://ncbi.nlm.nih.gov/pubmed/26372701
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2015.328
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados